A Study to Evaluate the Safety and Efficacy of CR845 in Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 269 participants.

Also called NCT03617536

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 269 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03617536
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03617536. Randomized; double masking; primary purpose treatment. Start 2018-07-05 (actual); primary completion 2019-10-24 (actual). Results posted on 2024-01-24.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Evaluate the Safety and Efficacy of CR845 in Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus
Condition
Chronic Kidney Diseases
Condition
Pruritus
Intervention (Drug)
CR845 0.25 mg Oral Tablet
Intervention (Drug)
CR845 0.5 mg Oral Tablet
Intervention (Drug)
CR845 1 mg Oral Tablet
Intervention (Drug)
Placebo Oral Tablet
Lead sponsor
Cara Therapeutics, Inc. (class: industry)

Record details

Record id
cardio:ct-nct03617536
Content hash
3d13ce7961f697f34b81fe79ae9466a09d2d0a2ce3c8c69733d6350badfea2d5